These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

105 related articles for article (PubMed ID: 9127399)

  • 41. The effects of Z13752A, a combined ACE/NEP inhibitor, on responses to coronary artery occlusion; a primary protective role for bradykinin.
    Rastegar MA; Marchini F; Morazzoni G; Vegh A; Papp JG; Parratt JR
    Br J Pharmacol; 2000 Feb; 129(4):671-80. PubMed ID: 10683191
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Upregulation of angiotensin II type 2 receptor and limitation of myocardial stunning by angiotensin II type 1 receptor blockers during reperfused myocardial infarction in the rat.
    Jugdutt BI; Menon V
    J Cardiovasc Pharmacol Ther; 2003 Sep; 8(3):217-26. PubMed ID: 14506547
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Effects of a new amiodarone-like agent, SR 33589, in comparison to amiodarone, D,L-sotalol, and lignocaine, on ischemia-induced ventricular arrhythmias in anesthetized pigs.
    Finance O; Manning A; Chatelain P
    J Cardiovasc Pharmacol; 1995 Oct; 26(4):570-6. PubMed ID: 8569217
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Effect of angiotensin II blockade on cardiac hypertrophy and remodelling: a review.
    Dahlöf B
    J Hum Hypertens; 1995 Nov; 9 Suppl 5():S37-44. PubMed ID: 8583480
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Delayed protection against ventricular arrhythmias by monophosphoryl lipid-A in a canine model of ischaemia and reperfusion.
    Végh A; György K; Rastegar MA; Papp JG; Parratt JR
    Eur J Pharmacol; 1999 Oct; 382(2):81-90. PubMed ID: 10528142
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Reduction of development of left ventricular hypertrophy in salt-loaded Dahl salt-sensitive rats by angiotensin II receptor inhibition.
    de Simone G; Devereux RB; Camargo MJ; Wallerson DC; Sealey JE; Laragh JH
    Am J Hypertens; 1996 Mar; 9(3):216-22. PubMed ID: 8695019
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Use of losartan to examine the role of the cardiac renin-angiotensin system in myocardial dysfunction during ischemia and reperfusion.
    Werrmann JG; Cohen SM
    J Cardiovasc Pharmacol; 1996 Feb; 27(2):177-82. PubMed ID: 8720414
    [TBL] [Abstract][Full Text] [Related]  

  • 48. The protective effects of CP-060S on ischaemia- and reperfusion- induced arrhythmias in anaesthetized rats.
    Koga T; Fukazawa M; Suzuki Y; Akima M; Adachi Y; Tamura K; Kato T; Kuromaru O
    Br J Pharmacol; 1998 Apr; 123(7):1409-17. PubMed ID: 9579737
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The role of mitochondrial K(ATP) channels in antiarrhythmic effects of ischaemic preconditioning in dogs.
    Végh A; Parratt JR
    Br J Pharmacol; 2002 Dec; 137(7):1107-15. PubMed ID: 12429584
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Angiotensin receptor antagonists.
    Goldsmith DJ
    Lancet; 1997 Apr; 349(9060):1255. PubMed ID: 9130973
    [No Abstract]   [Full Text] [Related]  

  • 51. [The medicine of the month. Losartan (Cozaar)].
    Scheen AJ
    Rev Med Liege; 1997 May; 52(5):367-9. PubMed ID: 9273640
    [No Abstract]   [Full Text] [Related]  

  • 52. Effects of losartan on neuroleptic-induced catalepsy in mice.
    Pires JG; Silva SR; Futuro-Neto HA
    Braz J Med Biol Res; 1996 Aug; 29(8):1045-7. PubMed ID: 9181088
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Left ventricular fibrosis in renovascular hypertensive rats. Effect of losartan and spironolactone.
    Nicoletti A; Heudes D; Hinglais N; Appay MD; Philippe M; Sassy-Prigent C; Bariety J; Michel JB
    Hypertension; 1995 Jul; 26(1):101-11. PubMed ID: 7607712
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hypotensive effect of losartan, a nonpeptide angiotensin II receptor antagonist, in essential hypertension.
    Tsunoda K; Abe K; Hagino T; Omata K; Misawa S; Imai Y; Yoshinaga K
    Am J Hypertens; 1993 Jan; 6(1):28-32. PubMed ID: 8427658
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Alpha-human atrial natriuretic peptide, carperitide, reduces infarct size but not arrhythmias after coronary occlusion/reperfusion in dogs.
    Takagi G; Kiuchi K; Endo T; Yamamoto T; Sato N; Nejima J; Takano T
    J Cardiovasc Pharmacol; 2000 Jul; 36(1):22-30. PubMed ID: 10892656
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [Comparative studies on the anti-arrhythmic and anti-fibrillatory effectiveness of verapamil and nifedipine following acute coronary artery occlusion and reperfusion].
    Gülker H; Thale J; Brisse B; Bender F
    Z Kardiol; 1984 Aug; 73(8):515-24. PubMed ID: 6495811
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Attenuation of the antiarrhythmic effects of ischaemic preconditioning by blockade of bradykinin B2 receptors.
    Vegh A; Papp JG; Parratt J
    Br J Pharmacol; 1994 Dec; 113(4):1167-72. PubMed ID: 7534181
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Involvement of the renin-angiotensin system in ischemic damage and reperfusion arrhythmias in the isolated perfused rat heart.
    Fleetwood G; Boutinet S; Meier M; Wood JM
    J Cardiovasc Pharmacol; 1991 Mar; 17(3):351-6. PubMed ID: 1711594
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Effects of chronic treatment with angiotensin converting enzyme inhibitor or an angiotensin receptor antagonist in two-kidney, one-clip hypertensive rats.
    Imamura A; Mackenzie HS; Lacy ER; Hutchison FN; Fitzgibbon WR; Ploth DW
    Kidney Int; 1995 May; 47(5):1394-402. PubMed ID: 7637269
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Effects of calcium channel blocking agents on reperfusion arrhythmias.
    Sheehan FH; Epstein SE
    Am Heart J; 1982 Jun; 103(6):973-7. PubMed ID: 7081038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.